Telmisartan, an angiotensin II receptor blocker, attenuates Prevotella intermedia lipopolysaccharide-induced production of nitric oxide and interleukin-1β in murine macrophages

Choe, So-Hui; Choi, Eun‐Young; Hyeon, Jin-Yi; Keum, Bo Ram; Choi, Inhee; Kim, Sung-Jo

doi:10.1016/j.intimp.2019.105750

Cited by 19 publications

(14 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To interpret the information retrieved in this systematic review properly, recent ex vivo studies regarding tRAS in the periodontal tissue and inflammation should also be considered. The study conducted by Choe et al in 2019 evaluated the influence of Telmisartan on inflammatory mediators in murine macrophages stimulated with LPS from Prevotella intermedia, an important periodontitisassociated species (Choe et al, 2019). They found out, that Telmisartan led to significant inhibition of LPS-induced generation of inflammatory mediators, such as IL-1β, which is in accordance with the presented data.…”

Section: Discussionsupporting

confidence: 77%

“…To assess the relative treatment rankings, the "surface under the cumulative ranking" (SUCRA) curve was used as well as mean ranks (Salanti et al, 2011). From the three assumptions: similarity, transitivity and consistency, to be satisfied a priori for the network meta-analysis similarity was satisfied by the PICOS procedure, consistency by statistical methods using global ("design-by treatment approach") and local approaches ("loop-specific approach") to assess inconsistency, and transitivity by logical interpretation of outcome interferences and the statistical consistency tests (Cipriani et al, 2013).…”

Section: Synthesis Of Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The tissue renin-angiotensin system (tRAS) and the impact of its inhibition on inflammation and bone loss in the periodontal tissue

Saravi

Lang²,

Ülkümen³

et al. 2020

eCM

View full text Add to dashboard Cite

Recently, the existence of the tissue renin-angiotensin system (tRAS) has been described for multiple tissues in humans, suggesting its fundamental role in the progression of inflammation and fibrosis. Evidence arises that tRAS might have an impact on the progression of periodontitis and bone loss. However, neither the role of tRAS nor its impact as a therapeutic target have been systematically evaluated for periodontal tissue. The present study sought to characterise tRAS in the periodontal tissue and the effect of its inhibition on periodontal inflammation and bone loss. This systematic review was performed according to the preferred reporting items for systematic reviews and meta analyses (PRISMA) statement. Literature was searched using Web of Science core collection (Web of Science), Medline (Ovid), Cochrane central register of controlled trials (Ovid), Cochrane database of systematic reviews (Ovid), Google Scholar databases and the references of the retrieved studies in March 2020. Information on study design, sample size, population, procedure, type of intervention, observation time, as well as information on sources of bias, was extracted and evaluated. From 455 identified articles, 17 were included in the qualitative synthesis and 11 were included in the quantitative synthesis. Outcomes of studies indicated that the inhibition of tRAS components led to a reduction of periodontal bone loss and inflammation, dependent on the inhibitor used. The findings suggested an important role of tRAS in the periodontal tissue and indicate a potential therapeutic approach for periodontal diseases.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Synthesis Of Resultsmentioning

confidence: 99%

The tissue renin-angiotensin system (tRAS) and the impact of its inhibition on inflammation and bone loss in the periodontal tissue

Saravi

Lang²,

Ülkümen³

et al. 2020

eCM

View full text Add to dashboard Cite

show abstract

“…The authors hypothesized that ACEI/ARB therapy has an indirect antiviral function by regulating the immune system and blocking inflammatory responses. The ACEi enalapril increased IL-10 and IL-2 levels [104] , and downregulated TNF-α, IL-12, IL-6, IL-1β and IL-8 production [106] , [107] , whereas telmisartan, an AT1R antagonist, decreased TNF-α, IL-6, IL-8 and IL-1β levels [108] , [109] , confirming the anti-inflammatory profile of ACEI/ARB drugs.…”

Section: Drug Repurposing For Covid-19 and Affected Cytokinesmentioning

confidence: 96%

Drug repurposing and cytokine management in response to COVID-19: A review

Heimfarth

Serafini

Martins-Filho

et al. 2020

International Immunopharmacology

View full text Add to dashboard Cite

Highlights Rational strategy to carry out drugs repurposing for management COVID-19 patients. Anti-inflammation therapy plays a pivotal role in the management COVID-19 patients. Drugs mitigate the cytokines production induced by SARS-CoV-2‘s immunological activation. Reduction in hyperinflammation lead to a decrease in multiple organ failure.

show abstract

“…LCN2/NGAL is increased in hypertensive patients and downregulated by ARB treatment [ 105 ]. ARB blockade reduces STAT1 phosphorylation induced by inflammation and IL-1β, leading to a predominant M2 macrophage phenotype [ 106 ]. ARBs downregulate TLR4, MyD88 and NF-kappa B expression [ 107 , 108 ] as well as the inflammasome [ 109 , 110 ].…”

Section: Discussionmentioning

confidence: 99%